143 related articles for article (PubMed ID: 6596459)
1. Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients.
Goldstein CS; Bomalaski JS; Zurier RB; Neilson EG; Douglas SD
Kidney Int; 1984 Nov; 26(5):733-40. PubMed ID: 6596459
[TBL] [Abstract][Full Text] [Related]
2. Release of hydrogen peroxide and expression of HLA-DR and transferrin receptors by monocytes and peritoneal macrophages from patients undergoing continuous ambulatory peritoneal dialysis and normal controls.
McGregor SJ; Brock JH; Briggs JD; Junor BJ
Clin Immunol Immunopathol; 1990 Aug; 56(2):151-8. PubMed ID: 2379325
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma (IFN-gamma) as in vitro enhancing factor of peritoneal macrophage defective bactericidal activity during continuous ambulatory peritoneal dialysis (CAPD).
Lamperi S; Carozzi S
Am J Kidney Dis; 1988 Mar; 11(3):225-30. PubMed ID: 3125740
[TBL] [Abstract][Full Text] [Related]
4. Properties of human peritoneal macrophages from continuous ambulatory peritoneal dialysis (CAPD) patients.
McGregor SJ; Brock JH; Briggs JD; Junor BJ
FEMS Microbiol Immunol; 1989 Apr; 1(5):303-4. PubMed ID: 2631872
[No Abstract] [Full Text] [Related]
5. Serial peritoneal macrophage function studies in new and established continuous ambulatory peritoneal dialysis patients.
Lin CY; Ku WL; Huang TP
Am J Nephrol; 1990; 10(5):368-73. PubMed ID: 1964368
[TBL] [Abstract][Full Text] [Related]
6. Long-term continuous ambulatory peritoneal dialysis reduces the expression of CD11b, CD14, CD16, and CD64 on peritoneal macrophages.
Cárcamo C; Fernández-Castro M; Selgas R; Jiménez C; Molina S; Vara F
Perit Dial Int; 1996; 16(6):582-9. PubMed ID: 8981525
[TBL] [Abstract][Full Text] [Related]
7. Expression of transferrin receptors by monocytes and peritoneal macrophages from renal failure patients treated by continuous ambulatory peritoneal dialysis (CAPD).
Moughal NA; McGregor SJ; Brock JH; Briggs JD; Junor BJ
Eur J Clin Invest; 1991 Dec; 21(6):592-6. PubMed ID: 1778220
[TBL] [Abstract][Full Text] [Related]
8. Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study.
Betjes MG; Tuk CW; Struijk DG; Krediet RT; Arisz L; Hoefsmit EC; Beelen RH
Kidney Int; 1993 Mar; 43(3):641-8. PubMed ID: 8455363
[TBL] [Abstract][Full Text] [Related]
9. Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis.
van Bronswijk H; Verbrugh HA; Heezius HC; van der Meulen J; Oe PL; Verhoef J
Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):368-73. PubMed ID: 3137037
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the peritoneal cellular immune system during CAPD shortly before a clinical peritonitis.
Betjes MG; Tuk CW; Visser CE; Zemel D; Krediet RT; Arisz L; Beelen RH
Nephrol Dial Transplant; 1994; 9(6):684-92. PubMed ID: 7970097
[TBL] [Abstract][Full Text] [Related]
11. Immunologic patterns in CAPD patients with peritonitis.
Lamperi S; Carozzi S
Clin Nephrol; 1988; 30 Suppl 1():S41-4. PubMed ID: 3052960
[TBL] [Abstract][Full Text] [Related]
12. Continuous ambulatory peritoneal dialysis impairs T lymphocyte selection in the peritoneum.
Fricke H; Hartmann J; Sitter T; Steldinger R; Rieber P; Schiffl H
Kidney Int; 1996 May; 49(5):1386-95. PubMed ID: 8731104
[TBL] [Abstract][Full Text] [Related]
13. Peritonitis in continuous ambulatory peritoneal dialysis: cytokines in peritoneal fluid and blood.
Enríquez J; Klínger J; Arturo JA; Delgado M; Tobar C; Mosquera M
Adv Perit Dial; 2002; 18():177-83. PubMed ID: 12402614
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal macrophages during peritonitis. Phenotypic studies.
Hart PH; Jones CA; Finlay-Jones JJ
Clin Exp Immunol; 1992 Jun; 88(3):484-91. PubMed ID: 1606734
[TBL] [Abstract][Full Text] [Related]
15. CAPD peritonitis induces the production of a novel peptide, daintain/allograft inflammatory factor-1.
Brauner A; Hertting O; Alkstrand E; Sandberg E; Chromek M; Chen ZW; Ostenson CG
Perit Dial Int; 2003; 23(1):5-13. PubMed ID: 12691501
[TBL] [Abstract][Full Text] [Related]
16. Activation of immunocompetent cells in the peritoneum of patients treated with CAPD.
Davies SJ; Suassuna J; Ogg CS; Cameron JS
Kidney Int; 1989 Oct; 36(4):661-8. PubMed ID: 2811064
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.
Carozzi S; Nasini MG; Ravera M; Sanna A; Tirotta A; Lamperi S
Adv Perit Dial; 1997; 13():7-12. PubMed ID: 9360642
[TBL] [Abstract][Full Text] [Related]
18. Reduced secretion of IL-1 beta by peritoneal cells from patients on continuous ambulatory peritoneal dialysis.
Hart PH; Jones CA; Jones KL; Finlay-Jones JJ
Immunol Cell Biol; 1993 Apr; 71 ( Pt 2)():99-107. PubMed ID: 8486401
[TBL] [Abstract][Full Text] [Related]
19. Peritonitis - does peritoneal dialysis modality make a difference?
Piraino B; Sheth H
Blood Purif; 2010; 29(2):145-9. PubMed ID: 20093820
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal macrophages from patients on continuous ambulatory peritoneal dialysis have an increased capability to release tumour necrosis factor during peritonitis.
Fieren MW; van den Bemd GJ; Bonta IL; Ben-Efraim S
J Clin Lab Immunol; 1991 Jan; 34(1):1-9. PubMed ID: 1667936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
